-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Given age, comorbidities, and immune dysfunction, Patients with CLL may have a particularly high risk of infection and have a poor prognosis associated with coronavirus-19 disease (COVID-19). Reliable analysis of the prognosis of CLL patients
, especially the examination of baseline characteristics and the effectiveness of CLL treatment, is essential for the proper management of CLL patients in the event of a new coronapneumonia pandemic.
Mato and others analyzed patients with symptomatic CLL who were diagnosed with COVID-19 infection in 43 international centres (n-198).
the hospitalization rate of these 198 patients was 90%.
the median age of confirmed COVID-19 infection was 70.5 years.
median CIRS score is 8 (range 4-32).
39% of patients were initially treated (observation and wait) and 61% had received at least one CLL treatment (median of two).
90 (45%) patients were treated with CLL when they were diagnosed with COVID-19, most lying with BTK inhibitors (BTKi, 76%).
median follow-up for 16 days with an overall fatality rate (CFR) of 33%. the probability of hospitalization, entering ICU, intubation and death due to COVID-19 hospitalization, intake and death of patients with
primary and previous treatment was similar, at 89% vs 90%, 35% vs 36%, 33% vs 25% and 37% vs 32%, respectively.
the treatment of BTKi CLL at the time of COVID-19 does not affect the patient's survival (CFR: 34% vs 35%).
this study suggests that CLL patients hospitalized with COVID-19 are at high risk of death regardless of the stage of CLL's disease or treatment status.
future epidemiological studies are needed to assess the risk of SARS-CoV-2 infection, and these data should be independently validated.
.